Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3

The Definition of Insulin Resistance Using HOMA-IR for Americans of Mexican Descent Using Machine Learning

(2011) Hui-Qi Qu et al.   PLoS One

Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads

(2010) K. Rajender Reddy et al.   GASTROENTEROLOGY

Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection

(2010) C. Pedersen et al.   JOURNAL OF VIRAL HEPATITIS

Lipid droplets and hepatitis C virus infection

(2009) John McLauchlan   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon α-2a and ribavirin

(2008) Michael W. Fried et al.   HEPATOLOGY

Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

(2008) Martin Lagging et al.   HEPATOLOGY